Evidence map›Paper›PMID 38486089›Full record

ArticleScientific reports2024

Solubility of α-synuclein species in the L62 mouse model of synucleinopathy.

Karima Schwab, Mandy Magbagbeolu, Franz Theuring, Charles R Harrington, Claude M Wischik, Gernot Riedel

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Karima SchwabSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Forester Hill, Aberdeen, AB25 2ZD, UK. karima.schwab@abdn.ac.uk.
Mandy MagbagbeoluInstitute of Pharmacology, Charité-Universitätsmedizin Berlin, Hessische Str. 3-4, 10115, Berlin, Germany.
Franz TheuringInstitute of Pharmacology, Charité-Universitätsmedizin Berlin, Hessische Str. 3-4, 10115, Berlin, Germany.
Charles R HarringtonSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Forester Hill, Aberdeen, AB25 2ZD, UK.
Claude M WischikSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Forester Hill, Aberdeen, AB25 2ZD, UK.
Gernot RiedelSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Forester Hill, Aberdeen, AB25 2ZD, UK.
Charité - Universitätsmedizin Berlin · DEUniversity of Aberdeen · GBTauRx (United Kingdom) · GB

Funding

TauRx Pharmaceuticals PAR1577
6 · The paper itself

Abstract

The accumulation of α-synuclein (α-Syn) into Lewy bodies is a hallmark of synucleinopathies, a group of neurological disorders that include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Small oligomers as well as larger fibrils of α-Syn have been suggested to induce cell toxicity leading to a degenerative loss of neurones. A richer understanding of α-Syn aggregation in disease, however, requires the identification of the different α-Syn species and the characterisation of their biochemical properties. We here aimed at a more in-depth characterisation of the α-Syn transgenic mice, Line 62 (L62), and examined the deposition pattern and solubility of human and murine α-Syn in these mice using immunohistochemical and biochemical methods. Application of multiple antibodies confirmed mAb syn204 as the most discriminatory antibody for human α-Syn in L62. Syn204 revealed an intense and widespread immunohistochemical α-Syn labelling in parietal cortex and hippocampus, and to a lower level in basal forebrain and hindbrain regions. The labelled α-Syn represented somatic inclusions as well as processes and synaptic endings. Biochemical analysis revealed a Triton-resistant human α-Syn pool of large oligomers, a second pool of small oligomers that was not resistant to solubilization with urea/Triton. A third SDS-soluble pool of intermediate sized aggregates containing a mixture of both, human and mouse α-Syn was also present. These data suggest that several pools of α-Syn can exist in neurones, most likely in different cellular compartments. Information about these different pools is important for the development of novel disease modifying therapies aimed at α-Syn.

Indexed as

Parkinson DiseaseSynucleinopathiesalpha-SynucleinAnimalsAntibodiesHumansMiceMice, TransgenicSolubilityalpha-SynucleinAntibodiesSnca protein, mouseAlpha-synucleinMouse modelParkinson’s diseaseProtein aggregationProtein solubility

Identifiers

PMID38486089
PMCPMC10940722
OpenAlexW4392792932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.